INTERNATIONAL IMMUNOPHARMACOLOGY

TABLE OF CONTENTS

- Description p.1
- Impact Factor p.2
- Abstracting and Indexing p.2
- Editorial Board p.2
- Guide for Authors p.4

DESCRIPTION

*International Immunopharmacology* is the primary vehicle for the publication of original research papers pertinent to the overlapping areas of **immunology, pharmacology, cytokine biology, immunotherapy, immunopathology** and **immunotoxicology**. Review articles that encompass these subjects are also welcome.

The subject material appropriate for submission includes:
- Clinical studies employing immunotherapy of any type including the use of: bacterial and chemical agents; thymic hormones, interferon, lymphokines, etc., in transplantation and diseases such as cancer, immunodeficiency, chronic infection and allergic, inflammatory or autoimmune disorders.
- Studies on the mechanisms of action of these agents for specific parameters of immune competence as well as the overall clinical state.
- Pre-clinical animal studies and in vitro studies on mechanisms of action with immunopotentiators, immunomodulators, immunoadjuvants and other pharmacological agents active on cells participating in immune or allergic responses.
- Pharmacological compounds, microbial products and toxicological agents that affect the lymphoid system, and their mechanisms of action.
- Agents that activate genes or modify transcription and translation within the immune response.
- Substances activated, generated, or released through immunologic or related pathways that are pharmacologically active.
- Production, function and regulation of cytokines and their receptors.
- Classical pharmacological studies on the effects of chemokines and bioactive factors released during immunological reactions.
- Studies on the nature and function of drug and hormone receptors on lymphocytes and other cells in the immune system.
- Studies of cell-derived or humoral factors that modify the immune system causing cytotoxicity, inducing antibody production and mediating inflammatory responses.
- The development of immunologically based assays and their application to disease, including assays for drugs, hormones, cyclic nucleotides, tumor antigens, etc.
- The Editors will be pleased to receive published books for possible independent review.

Please Bookmark this URL: http://www.elsevier.com/locate/intimp

*Backfiles_Banner_sml.gif* ScienceDirect Backfiles

These Backfiles include *Immunopharmacology* and the *International Journal of Immunopharmacology*. 
IMPACT FACTOR

2018: 3.361 © Clarivate Analytics Journal Citation Reports 2019

ABSTRACTING AND INDEXING

Scopus
SIIC Data Bases
Current Contents - Life Sciences and Clinical Medicine
Science Citation Index
Cambridge Scientific Abstracts
Chemical Abstracts
Embase
PubMed/Medline
Pascal Francis
Current Awareness in Biological Sciences
Elsevier BIOBASE

EDITORIAL BOARD

Editor-in-Chief
J.E. Talmadge, University of Nebraska Department of Pathology and Microbiology, Nebraska Medical Center, 42ns and Emile, Omaha, Nebraska, NE 68198-3135, United States, Fax: +1 402 559-4990

Associate Editors
A. Barber, John H and Karen Williams Chichester Science Center, 201 High Street, Farmville, Virginia, VA 23909, United States, Fax: +1 434-395-2652
L. Cao, University of New England Department of Biomedical Sciences, 11 Hills Beach Road, Biddeford, Maine, ME 04005, United States, Fax: +1 207-602-5931
H. Haase, TU Berlin Department of Food Chemistry and Toxicology, Gustav-Meyer-Allee 25, 13355, Berlin, Germany
N. Hirasawa, Tohoku University Graduate School of Pharmaceutical Sciences Faculty of Pharmaceutical Sciences, 6-3 Aoba, Aramaki, Aoba-ku, 980-8578, Sendai, Japan
M. Kawada, Numazu Microbial Chemistry Research Foundation Institute of Microbial Chemistry Laboratory of Oncology, 3-14-23 Kamiosaki, Shinagawa-ku, 141-0021, Tokyo, Japan
H. Kobayashi, Chiba University Graduate School of Pharmaceutical Sciences Faculty of Pharmaceutical Sciences, 1-8-1 Inohana, Chuo-ku, 260-8675, Chiba, Japan
F. Marceau, Centre de Recherche du CHU de Québec, Centre de recherche en rhumatologie et immunologie, 2705 Laurier Blvd., Room T1-49, Québec City, G1V 4G2, Canada, Fax: +1 418 654 2765
P.T. Peachell, University of Sheffield Medical School, Academic Unit of Respiratory, Beech Hill Road, S10 2RX, Sheffield, United Kingdom, Fax: +44 114 272 0275
J.M. Wang, Laboratory of Molecular Immunoregulation, Frederick, Maryland, MD 21702-1201, United States, Fax: +1 301 846 7042
L.A. Zenewicz, University of Oklahoma Department of Microbiology and Immunology, 920 Stanton L. Young Blvd., Oklahoma City, Oklahoma, OK 73104, United States, Fax: +1 405.271.3117

Founding Co-Editor-in-Chief
T.E. Hugli, San Diego, California, United States

Editorial Board
J. Actor, University of Texas Health Science Center at Houston, Houston, Texas, United States
S. Basu, OHIO STATE UNIVERSITY, Columbus, Ohio, United States
K.A. Brown, Saint Thomas’ Hospital, London, United Kingdom
D. Capone, University of Naples Federico II, Napoli, Italy
K. Chen, Center for Cancer Research, Frederick, Maryland, United States
S. Chirumbolo, University of Verona, Verona, Italy
V.J. Coulson-Thomas, University of Houston, Houston, Texas, United States
S. Fiering, Dartmouth College Geisel School of Medicine, Hanover, New Hampshire, United States
A. Fioravanti, Siena University Hospital, Siena, Italy
H. Fujii, Janssen Pharmaceutical KK, Chiyoda-ku, Tokyo, Japan
R. M. Gogal, The University of Georgia, Athens, Georgia, United States
L. Hou, Harvard Medical School, Boston, Massachusetts, United States
N. Inagaki, Gifu Pharmaceutical University, Gifu, Japan
P. Iribarren, National University of Cordoba, Cordoba, Argentina
Y. Kawakami, Keio University School of Medicine Graduate School of Medicine, Shinjuku-Ku, Japan
M. Lang, University of Oklahoma Department of Microbiology and Immunology, Oklahoma City, Oklahoma, United States
A. Liu, Huazhong University of Science and Technology, Wuhan, China
E. Liverani, Temple University, Philadelphia, Pennsylvania, United States
S. J. Merrill, Marquette University, Milwaukee, Wisconsin, United States
D.W. Mullins, Dartmouth College Department of Microbiology & Immunology, Hanover, New Hampshire, United States
R. Nicolete
J.J. Obar, Dartmouth Geisel Medical School Community and Family Medicine, Lebanon, New Hampshire, United States
R. Pal, King George's Medical University Department of Pharmacology and Therapeutics, Lucknow, Uttar Pradesh, India
M. A. Panaro, University of Bari, Bari, Italy
J. Peng, Dalian Medical University College of Pharmacy, Dalian, China
T.M. Petro, University of Nebraska Department of Oral Biology, Lincoln, Nebraska, United States
P. Pioli, Dartmouth Geisel Medical School Community and Family Medicine, Lebanon, New Hampshire, United States
R.T. Robinson, OHIO STATE UNIVERSITY, Columbus, Ohio, United States
U. Švajger, Republic of Slovenia Institute of Transfusion Medicine, Ljubljana, Slovenia
M.J. Turk, Dartmouth Geisel Medical School Community and Family Medicine, Lebanon, New Hampshire, United States
S. Umar, University of Illinois at Chicago College of Medicine, Chicago, Illinois, United States
M. Vincenti, White River Junction VA Medical Center, White River Junction, Vermont, United States
J. Wang, Henan University of Technology, Zhengzhou, China
C.F. Wu, Shenyang Pharmaceutical University, Shenyang, China
G. Xanthou, Biomedical Research Foundation of the Academy of Athens, Athens, Greece
M. Rita I. Young, Ralph H. Johnson VA Medical Center, Research Service (151) and Medical University of South Carolina (MUSC), Columbia, South Carolina, United States
Zhang, DUKE UNIVERSITY MEDICAL CENTER, Durham, North Carolina, United States
Zhang, Army Medical University, Chongqing, China
GUIDE FOR AUTHORS

Your Paper Your Way
We now differentiate between the requirements for new and revised submissions. You may choose to submit your manuscript as a single Word or PDF file to be used in the refereeing process. Only when your paper is at the revision stage, will you be requested to put your paper in to a 'correct format' for acceptance and provide the items required for the publication of your article.
To find out more, please visit the Preparation section below.

INTRODUCTION
International Immunopharmacology is an interdisciplinary journal devoted to the publication of original scientific papers interrelating immunology and pharmacology. Manuscripts will be considered for publication on the condition that the results reported are based on original research that has not been published elsewhere in any journal or language.

Types of Paper

• **Full-length articles** are full-length descriptions of original research. The scope may include basic science, clinical results, or applications. These manuscripts will undergo standard review. We emphasize that papers on natural products must meet the following specific criteria: a) any natural extract or drug should be fully characterized and information provided regarding origin - specifically, the "drug" under study must have been fractionated and the active substances within the natural product identified; b) isolation or purification techniques must be described in detail; and c) the authors must state in their paper that the material under study is endotoxin free, including not only natural products, but also all biologics and synthetics used for immunopharmacologic studies. The Editor-in-Chief requests that authors of Natural Product contributions read the guidelines as set out in the Editorial article of International Immunopharmacology volume 6, issue 8.

• **Short Communications.** These are short manuscripts that have important and generally conclusionary data on a specific issue. They should consist of no more than 3000 words with up to an additional 20 references and two tables and/or figures.

• **Preliminary Studies/Reports.** This section is for the publication of new observations that are promising but have not achieved the stature of a regular article, yet are judged by the reviewers or editorial staff to contribute a novel, important, or useful observation worthy of publication. These reports, including clinical studies on a limited patient population, will generally be brief reports of a single or a few observations or results comprising up to four printed pages including all references and display items; appropriate statistical analyses should be included.

• **Reviews** are comprehensive appraisals of research and clinical outcomes in a field of current interest. Potential authors are instructed to contact the Editor-in-Chief first regarding topic and suitability. All reviews are subject to the normal review process.

• **Invited Commentary.** Topical editorials, commentaries, prospective reviews and hypotheses demonstrating acceptable standards of originality. Such articles will only be published following an invitation to the author(s) from an Editor. Other prospective authors should obtain editorial permission before submitting a manuscript. Commentaries (3000 words) will serve as the means for expressing controversial, critical and often personal evaluations of research trends. Commentaries in the form of prospective reviews or hypotheses will be composite presentations of wide-ranging observations from the literature, which should indicate, and possibly stimulate, new directions for potentially rewarding immunopharmacological research.

• **Letters to the Editor** may be considered at the discretion of the Editors.

• **Book Reviews.** Books for review may be sent to the Editor-in-Chief. Authors interested in reviewing a particular book should communicate directly with him.

• **Meeting/Symposia reports** are synopses of meetings and symposia, generally shorter than five journal pages. Please contact the Editor-in-Chief prior to submitting. Reports must be submitted within two weeks of the end of the meeting.

• **Special Issues or Thematic Reports** are collections of full-length articles and/or reviews on a specific topic. These require approval by the Editor-in-Chief; however, recommendations or suggestions are encouraged.

Submission checklist
You can use this list to carry out a final check of your submission before you send it to the journal for review. Please check the relevant section in this Guide for Authors for more details.
Ensure that the following items are present:

One author has been designated as the corresponding author with contact details:
- E-mail address
- Full postal address

All necessary files have been uploaded:

**Manuscript:**
- Include keywords
- All figures (include relevant captions)
- All tables (including titles, description, footnotes)
- Ensure all figure and table citations in the text match the files provided
- Indicate clearly if color should be used for any figures in print

**Graphical Abstracts / Highlights files** (where applicable)

**Supplemental files** (where applicable)

Further considerations
- Manuscript has been 'spell checked' and 'grammar checked'
- All references mentioned in the Reference List are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Internet)
- A competing interests statement is provided, even if the authors have no competing interests to declare
- Journal policies detailed in this guide have been reviewed
- Referee suggestions and contact details provided, based on journal requirements

For further information, visit our Support Center.

**BEFORE YOU BEGIN**

**Ethics in publishing**
Please see our information pages on Ethics in publishing and Ethical guidelines for journal publication.

**Policy and ethics**
Upon acceptance for publication of an article in International Immunopharmacology, the author tacitly agrees to make available any materials used in the published experiments, or novel or natural products disclosed in the article that are not commercially available, so that qualified investigators may confirm the observations.

**Declaration of interest**
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential competing interests include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors must disclose any interests in two places: 1. A summary declaration of interest statement in the title page file (if double-blind) or the manuscript file (if single-blind). If there are no interests to declare then please state this: 'Declarations of interest: none'. This summary statement will be ultimately published if the article is accepted. 2. Detailed disclosures as part of a separate Declaration of Interest form, which forms part of the journal's official records. It is important for potential interests to be declared in both places and that the information matches. More information.

**Submission declaration and verification**
Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see 'Multiple, redundant or concurrent publication' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service Crossref Similarity Check.
Preprints
Please note that preprints can be shared anywhere at any time, in line with Elsevier's sharing policy. Sharing your preprints e.g. on a preprint server will not count as prior publication (see 'Multiple, redundant or concurrent publication' for more information).

Use of inclusive language
Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Articles should make no assumptions about the beliefs or commitments of any reader, should contain nothing which might imply that one individual is superior to another on the grounds of race, sex, culture or any other characteristic, and should use inclusive language throughout. Authors should ensure that writing is free from bias, for instance by using 'he or she', 'his/her' instead of 'he' or 'his', and by making use of job titles that are free of stereotyping (e.g. 'chairperson' instead of 'chairman' and 'flight attendant' instead of 'stewardess').

Author contributions
For transparency, we encourage authors to submit an author statement file outlining their individual contributions to the paper using the relevant CRediT roles: Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Roles/Writing - original draft; Writing - review & editing. Authorship statements should be formatted with the names of authors first and CRediT role(s) following. More details and an example

Authorship
All authors should have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted.

Changes to authorship
Authors are expected to consider carefully the list and order of authors before submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only before the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the corresponding author: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.

Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors after the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

Article transfer service
This journal is part of our Article Transfer Service. This means that if the Editor feels your article is more suitable in one of our other participating journals, then you may be asked to consider transferring the article to one of those. If you agree, your article will be transferred automatically on your behalf with no need to reformat. Please note that your article will be reviewed again by the new journal. More information.

Copyright
Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see more information on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases.
For gold open access articles: Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' (more information). Permitted third party reuse of gold open access articles is determined by the author's choice of user license.

**Author rights**
As an author you (or your employer or institution) have certain rights to reuse your work. More information.

**Elsevier supports responsible sharing**
Find out how you can share your research published in Elsevier journals.

**Role of the funding source**
You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

**Funding body agreements and policies**
Elsevier has established a number of agreements with funding bodies which allow authors to comply with their funder's open access policies. Some funding bodies will reimburse the author for the gold open access publication fee. Details of existing agreements are available online.

**Open access**
This journal offers authors a choice in publishing their research:

**Subscription**
- Articles are made available to subscribers as well as developing countries and patient groups through our universal access programs.
- No open access publication fee payable by authors.
- The Author is entitled to post the accepted manuscript in their institution's repository and make this public after an embargo period (known as green Open Access). The published journal article cannot be shared publicly, for example on ResearchGate or Academia.edu, to ensure the sustainability of peer-reviewed research in journal publications. The embargo period for this journal can be found below.

**Gold open access**
- Articles are freely available to both subscribers and the wider public with permitted reuse.
- A gold open access publication fee is payable by authors or on their behalf, e.g. by their research funder or institution.

Regardless of how you choose to publish your article, the journal will apply the same peer review criteria and acceptance standards.

For gold open access articles, permitted third party (re)use is defined by the following Creative Commons user licenses:

**Creative Commons Attribution (CC BY)**
Lets others distribute and copy the article, create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), include in a collective work (such as an anthology), text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

**Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)**
For non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

The gold open access publication fee for this journal is **USD 3300**, excluding taxes. Learn more about Elsevier's pricing policy: [https://www.elsevier.com/openaccesspricing](https://www.elsevier.com/openaccesspricing).

**Green open access**
Authors can share their research in a variety of different ways and Elsevier has a number of green open access options available. We recommend authors see our open access page for further information. Authors can also self-archive their manuscripts immediately and enable public access from their
institution’s repository after an embargo period. This is the version that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and in editor-author communications. Embargo period: For subscription articles, an appropriate amount of time is needed for journals to deliver value to subscribing customers before an article becomes freely available to the public. This is the embargo period and it begins from the date the article is formally published online in its final and fully citable form. Find out more.

This journal has an embargo period of 12 months.

Elsevier Researcher Academy
Researcher Academy is a free e-learning platform designed to support early and mid-career researchers throughout their research journey. The "Learn" environment at Researcher Academy offers several interactive modules, webinars, downloadable guides and resources to guide you through the process of writing for research and going through peer review. Feel free to use these free resources to improve your submission and navigate the publication process with ease.

Language (usage and editing services)
Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier’s Author Services.

Submission
Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

For online submission to this journal please visit: https://www.evise.com/profile/api/navigate/INTIMP.

Submit your article
Please submit your article via https://www.evise.com/profile/api/navigate/INTIMP

Referees
Authors are encouraged to provide the names, addresses, e-mail addresses and fax numbers of up to four researchers qualified to review the manuscript.

PREPARATION
NEW SUBMISSIONS
Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts your files to a single PDF file, which is used in the peer-review process. As part of the Your Paper Your Way service, you may choose to submit your manuscript as a single file to be used in the refereeing process. This can be a PDF file or a Word document, in any format or layout that can be used by referees to evaluate your manuscript. It should contain high enough quality figures for refereeing. If you prefer to do so, you may still provide all or some of the source files at the initial submission. Please note that individual figure files larger than 10 MB must be uploaded separately.

References
There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the article number or pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct.

Formatting requirements
There are no strict formatting requirements but all manuscripts must contain the essential elements needed to convey your manuscript, for example Abstract, Keywords, Introduction, Materials and Methods, Results, Conclusions, Artwork and Tables with Captions.
If your article includes any Videos and/or other Supplementary material, this should be included in your initial submission for peer review purposes. Divide the article into clearly defined sections.

Please ensure the text of your paper is double-spaced - this is an essential peer review requirement.

Figures and tables embedded in text
Please ensure the figures and the tables included in the single file are placed next to the relevant text in the manuscript, rather than at the bottom or the top of the file. The corresponding caption should be placed directly below the figure or table.

Peer review
This journal operates a single blind review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. More information on types of peer review.

REVISED SUBMISSIONS
Use of word processing software
Regardless of the file format of the original submission, at revision you must provide us with an editable file of the entire article. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier). See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

Article structure
Subdivision - numbered sections
Divide your article into clearly defined and numbered sections. Subsections should be numbered 1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this numbering also for internal cross-referencing: do not just refer to 'the text'. Any subsection may be given a brief heading. Each heading should appear on its own separate line.

Introduction
An Introduction should first "set the scene" for a non-specialist and then continue with the specific reasons for undertaking the investigation. Exhaustive reviews of the literature should be avoided and no attempt should be made to indicate the results obtained.

Materials and Methods. Authors should describe details of the design, subjects, and methods for all studies. Sufficient details need to be provided such that the study can be replicated by others. Consistent with this the figure legends should contain sufficient information so that there is no need to frequently refer to the Methods. If well-established methods are used, provide a reference to the technique and full details of any modifications. Instruments used should be accompanied by their model name, city, state and country of manufacture in parenthesis. The clone name and source of monoclonal antibodies need to be reported. The statistical and software program(s) used should be described.

Cell lines: The misidentification or contamination of cell lines adversely impacts the validity of research observations. Authors should describe the source of the cell line, along with the date and method used for authentication, in the Materials and Methods section. The source and method of virus/mycoplasma assessment should also be identified in the Materials and Methods section.

Animal studies: Appropriate IACUC approval should be obtained and described. Animal species/ strain, sex, and source (vendor name, location) should be indicated. Information regarding animal housing (type of facility e.g. specific pathogen free [SPF]; type of cage or housing; bedding material; and number of cage companions) should be provided. Further, husbandry conditions (e.g. breeding program, light/dark cycle, temperature, quality of water etc., access to food and water, and environmental enrichment) also should be discussed. We encourage the use of both female and male animals; use of a single sex should be scientifically justified.
An explanation of how samples and animals were randomized to treatment should be provided, and a valid scientific justification discussed if this was not undertaken. An explanation of how the operator and data analyst were blinded should be provided, and if blinding was not undertaken, a valid scientific justification should be provided.

**Human Studies:** Informed consent must be obtained for studies on humans. A statement that informed consent was obtained must also appear in the manuscript. All research on humans must have approval from the institutional IRB (Institutional Review Board) or equivalent. Gender and age of all subjects should be provided in the main text or Supplementary Materials.

**Natural compounds:** The journal applies specific guidelines for manuscripts dealing with drugs extracted from natural products: see International Immunopharmacology 2016;37:3. Briefly, the compound under study should be purified to homogeneity, its structure known and it should be substantially endotoxin-free if injected in vivo or applied to cultured cells.

**Graphs, Histograms and Statistics:** Data and error bars must be described in the figure legend (for example, "data are presented as means +/- standard deviation"). Axes on graphs should extend to zero, except for log axes. Statistical analyses (including error bars and \( P \) values) should only be shown for independently repeated experiments and must not be shown for replicates of a single experiment. The number of times an experiment was independently repeated must be stated in the legend, as well as, the N as appropriate.

It is the author's responsibility to document that the results are reproducible and that the differences found are not due to random variation. No absolute rules to this requirement can be applied but, in general, quantitative data should be from no fewer than three independent, replicate experiments conducted during non-overlapping time spans. Appropriate statistical methods should be used to test the significance of differences in the results. Depending on the data variability the results from multiple independent experiments can be pooled, analyzed and presented. Alternatively, authors can include separate sets of results from independent, critical experiments to document consistency. The term 'significant' should not be used unless statistical analysis was performed, and the probability value used to identify significance (e.g. \( P < 0.05 \)) should be specified.

When several t-tests are employed, nominal probability levels are no longer appropriate. Accordingly, the multiple t-test, multiple range test, or similar techniques to permit simultaneous comparisons should be utilized. Further, rather than using several t-tests, it is more appropriate to utilize an analysis of variance (ANOVA) test to allow pooling of data, increase the number of degrees of freedom, and improve the result reliability. Authors should use appropriate nonparametric tests when results do not form a normal distribution. If transformation is employed to achieve normal distribution prior statistical analysis, the type if transformation should be reported.

**Results.** In this section the findings should be described without discussion of their significance. Subsections should be used to clarify the expression of the results.

**Discussion.** In this section the authors' interpretations of their findings should be accompanied by an assessment of their significance in relation to previous work. Subsections should be used wherever possible.

**Essential title page information**

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
- **Author names and affiliations.** Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. You can add your name between parentheses in your own script behind the English transliteration. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
- **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. This responsibility includes answering any future queries about Methodology and Materials. **Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.**
• **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

**Highlights**

Highlights are mandatory for this journal as they help increase the discoverability of your article via search engines. They consist of a short collection of bullet points that capture the novel results of your research as well as new methods that were used during the study (if any). Please have a look at the examples here: example Highlights.

Highlights should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point).

**Abstract**

Each paper must begin with an Abstract that summarizes the results obtained and the conclusions drawn. It should not exceed 250 words.

**Graphical abstract**

Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online article. The graphical abstract should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. You can view Example Graphical Abstracts on our information site.

Authors can make use of Elsevier's Illustration Services to ensure the best presentation of their images and in accordance with all technical requirements.

**Keywords**

Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

**Abbreviations**

The excessive use of abbreviations in the text is strongly discouraged. In particular, awkward and unfamiliar abbreviations and those intended to express concepts or experimental techniques will not be permitted.

**Formatting of funding sources**

List funding sources in this standard way to facilitate compliance to funder's requirements:

Funding: This work was supported by the National Institutes of Health [grant numbers xxxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzzz]; and the United States Institutes of Peace [grant number aaaa].

It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.

If no funding has been provided for the research, please include the following sentence:

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Nomenclature and Units**

- Drug names should be the official or approved names; trade names or common names may be given in brackets where the drug is first mentioned. The manufacturer's name and address must be given. The doses of the drugs should be given as unit weight/unit body weight, e.g. mmol/kg or mg/kg. Concentrations should be given in terms of molarity (e.g. nM or uM), or as unit weight/unit.
volume solution (eg. mg/l) stating whether the weight refers to the salt or the active component of the drug. The molecular weight, inclusive of water of crystallization, should be stated if doses are given as unit weight.

- Isotopic specifications should conform to the IUPAC system (Biochem. J. (1975) 145, 1-20).

- The IUB Enzyme Commission (EC) number must be quoted with the full name of the enzyme when it is first mentioned in the text. Subsequently the accepted trivial name shall be used, e.g. Full Name: Acetyl-CoA:choline O-acetyltransferase (EC 2.3.1.6.) Trivial Name: Choline acetyltransferase not choline acetylase. For this information the author should refer to Enzyme Nomenclature (1973), Elsevier, Amsterdam.

- Authors are requested to follow the IUPHAR Guidelines for Classification of New Receptor Subtypes (see Immunopharmacology, Vol. 30, p. 189 or p. 255).

- Symbols for physical units should be restricted to the Systeme Internationale (S.I.) Units. Examples of commonly used symbols can be found in Biochemical Journal 145, 1-20 (1975) and more detailed description, in Quantities, Units and Symbols (1971) The Royal Society, London.

Footnotes
Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors build footnotes into the text, and this feature may be used. Should this not be the case, indicate the position of footnotes in the text and present the footnotes themselves separately at the end of the article.

Artwork
Electronic artwork
General points
- Make sure you use uniform lettering and sizing of your original artwork.
- Preferred fonts: Arial (or Helvetica), Times New Roman (or Times), Symbol, Courier.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Indicate per figure if it is a single, 1.5 or 2-column fitting image.
- For Word submissions only, you may still provide figures and their captions, and tables within a single file at the revision stage.
- Please note that individual figure files larger than 10 MB must be provided in separate source files.

A detailed guide on electronic artwork is available.

You are urged to visit this site; some excerpts from the detailed information are given here.

Formats
Regardless of the application used, when your electronic artwork is finalized, please 'save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS (or PDF): Vector drawings. Embed the font or save the text as 'graphics'.
TIFF (or JPG): Color or grayscale photographs (halftones): always use a minimum of 300 dpi.
TIFF (or JPG): Bitmapped line drawings: use a minimum of 1000 dpi.
TIFF (or JPG): Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi is required.

Please do not:
- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is too low.
- Supply files that are too low in resolution.
- Submit graphics that are disproportionately large for the content.

Color artwork
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. For color reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article. Please indicate your preference for color: in print or online only. Further information on the preparation of electronic artwork.
Figure captions
Ensure that each illustration has a caption. A caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

Tables
Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.

References
Citation in text
Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

Web references
As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

Data references
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct. If you do wish to format the references yourself they should be arranged according to the following examples:
Reference style

Text: Indicate references by number(s) in square brackets in line with the text. The actual authors can be referred to, but the reference number(s) must always be given. Example: '..... as demonstrated [3,6]. Barnaby and Jones [8] obtained a different result ....'

List: Number the references (numbers in square brackets) in the list in the order in which they appear in the text.

Examples:

Reference to a journal publication:
Reference to a journal publication with an article number:
Reference to a book:
Reference to a chapter in an edited book:
Reference to a website:
Reference to a dataset:

Video

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the file in one of our recommended file formats with a preferred maximum size of 150 MB per file, 1 GB in total. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

Data visualization

Include interactive data visualizations in your publication and let your readers interact and engage more closely with your research. Follow the instructions here to find out about available data visualization options and how to include them with your article.

Supplementary material

Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.

Research data

This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings. To facilitate reproducibility and data reuse, this journal also encourages you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the project.
Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the research data page.

Data linking
If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.

There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the database linking page.

For supported data repositories a repository banner will automatically appear next to your published article on ScienceDirect.

In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

Mendeley Data
This journal supports Mendeley Data, enabling you to deposit any research data (including raw and processed data, video, code, software, algorithms, protocols, and methods) associated with your manuscript in a free-to-use, open access repository. During the submission process, after uploading your manuscript, you will have the opportunity to upload your relevant datasets directly to Mendeley Data. The datasets will be listed and directly accessible to readers next to your published article online.

For more information, visit the Mendeley Data for journals page.

Data in Brief
You have the option of converting any or all parts of your supplementary or additional raw data into one or multiple data articles, a new kind of article that houses and describes your data. Data articles ensure that your data is actively reviewed, curated, formatted, indexed, given a DOI and publicly available to all upon publication. You are encouraged to submit your article for Data in Brief as an additional item directly alongside the revised version of your manuscript. If your research article is accepted, your data article will automatically be transferred over to Data in Brief where it will be editorially reviewed and published in the open access data journal, Data in Brief. Please note an open access fee of 600 USD is payable for publication in Data in Brief. Full details can be found on the Data in Brief website. Please use this template to write your Data in Brief.

Data statement
To foster transparency, we encourage you to state the availability of your data in your submission. This may be a requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. The statement will appear with your published article on ScienceDirect. For more information, visit the Data Statement page.

AFTER ACCEPTANCE

Online proof correction
Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.
If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.
We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

**Offprints**
The corresponding author will, at no cost, receive a customized Share Link providing 50 days free access to the final published version of the article on ScienceDirect. The Share Link can be used for sharing the article via any communication channel, including email and social media. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's Author Services. Corresponding authors who have published their article gold open access do not receive a Share Link as their final published version of the article is available open access on ScienceDirect and can be shared through the article DOI link.

**AUTHOR INQUIRIES**
Visit the Elsevier Support Center to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch.
You can also check the status of your submitted article or find out when your accepted article will be published.

© Copyright 2018 Elsevier | https://www.elsevier.com